Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018715875> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2018715875 endingPage "S26" @default.
- W2018715875 startingPage "S21" @default.
- W2018715875 abstract "Hepatitis B virus infection is preventable by vaccine and the correlate of immunity is the induction of antibody. The 2.5 μg antigen per dose of H-B-VAX II given in appropriate regimens is adequate to immunize normal newborn infants and children up to 11 years of age. A 5 μg dose may be needed to protect newborn infants born to mothers who are carriers of hepatitis B infection and should be used when the carrier status is either positive or is unknown. The immune response in newborn infants is usually of lower titre than in infants who are 2–3 months of age or older. The level of protection afforded in otherwise healthy individuals by plasma-derived vaccine is high and lasts for longer than 7 years, even though the level of circulating antibody may have declined to a less than detectable amount. A similar pattern of antibody decline follows administration of recombinant vaccine. The mechanism for sustained protection is in long-term immunological memory with rapid recall of antibody production on exposure to the virus in nature. Administration of hepatitis B vaccine will be simplified by combination with DPT and poliomyelitis vaccines in single-dose formulations that are under current development. An experimentally killed hepatitis A virus vaccine prepared by formaldehyde inactivation of attenuated live virus purified from infected MRC-5 cell cultures induces rapid and high level antibody response when the vaccine is given in as little as 100 ng of antigen per dose and in two- or three-dose regimens. The vaccine is highly protective when assayed in challenge studies in animals and the levels of antibodies achieved are far in excess of those provided by immune globulin when used for passive protection in humans. Field investigations to demonstrate protective efficacy against natural challenge in human beings have been in progress and protective efficacy has been established." @default.
- W2018715875 created "2016-06-24" @default.
- W2018715875 creator A5010667348 @default.
- W2018715875 creator A5010855970 @default.
- W2018715875 creator A5016402681 @default.
- W2018715875 creator A5035838766 @default.
- W2018715875 creator A5043805146 @default.
- W2018715875 creator A5065092216 @default.
- W2018715875 date "1993-01-01" @default.
- W2018715875 modified "2023-09-23" @default.
- W2018715875 title "Vaccines against hepatitis A and B" @default.
- W2018715875 cites W1941247615 @default.
- W2018715875 cites W1986203829 @default.
- W2018715875 cites W1987204510 @default.
- W2018715875 cites W2005240718 @default.
- W2018715875 cites W2010374353 @default.
- W2018715875 cites W2054724014 @default.
- W2018715875 cites W2309477817 @default.
- W2018715875 cites W2320159189 @default.
- W2018715875 cites W2337114621 @default.
- W2018715875 doi "https://doi.org/10.1111/j.1440-1746.1993.tb01676.x" @default.
- W2018715875 hasPublicationYear "1993" @default.
- W2018715875 type Work @default.
- W2018715875 sameAs 2018715875 @default.
- W2018715875 citedByCount "5" @default.
- W2018715875 crossrefType "journal-article" @default.
- W2018715875 hasAuthorship W2018715875A5010667348 @default.
- W2018715875 hasAuthorship W2018715875A5010855970 @default.
- W2018715875 hasAuthorship W2018715875A5016402681 @default.
- W2018715875 hasAuthorship W2018715875A5035838766 @default.
- W2018715875 hasAuthorship W2018715875A5043805146 @default.
- W2018715875 hasAuthorship W2018715875A5065092216 @default.
- W2018715875 hasConcept C147483822 @default.
- W2018715875 hasConcept C159047783 @default.
- W2018715875 hasConcept C159654299 @default.
- W2018715875 hasConcept C203014093 @default.
- W2018715875 hasConcept C22070199 @default.
- W2018715875 hasConcept C2522874641 @default.
- W2018715875 hasConcept C2777382497 @default.
- W2018715875 hasConcept C2777410769 @default.
- W2018715875 hasConcept C2779341262 @default.
- W2018715875 hasConcept C2780593183 @default.
- W2018715875 hasConcept C2781037505 @default.
- W2018715875 hasConcept C32611913 @default.
- W2018715875 hasConcept C71924100 @default.
- W2018715875 hasConcept C8891405 @default.
- W2018715875 hasConceptScore W2018715875C147483822 @default.
- W2018715875 hasConceptScore W2018715875C159047783 @default.
- W2018715875 hasConceptScore W2018715875C159654299 @default.
- W2018715875 hasConceptScore W2018715875C203014093 @default.
- W2018715875 hasConceptScore W2018715875C22070199 @default.
- W2018715875 hasConceptScore W2018715875C2522874641 @default.
- W2018715875 hasConceptScore W2018715875C2777382497 @default.
- W2018715875 hasConceptScore W2018715875C2777410769 @default.
- W2018715875 hasConceptScore W2018715875C2779341262 @default.
- W2018715875 hasConceptScore W2018715875C2780593183 @default.
- W2018715875 hasConceptScore W2018715875C2781037505 @default.
- W2018715875 hasConceptScore W2018715875C32611913 @default.
- W2018715875 hasConceptScore W2018715875C71924100 @default.
- W2018715875 hasConceptScore W2018715875C8891405 @default.
- W2018715875 hasIssue "S1" @default.
- W2018715875 hasLocation W20187158751 @default.
- W2018715875 hasOpenAccess W2018715875 @default.
- W2018715875 hasPrimaryLocation W20187158751 @default.
- W2018715875 hasRelatedWork W2011723009 @default.
- W2018715875 hasRelatedWork W2072712054 @default.
- W2018715875 hasRelatedWork W2078884611 @default.
- W2018715875 hasRelatedWork W2307318487 @default.
- W2018715875 hasRelatedWork W2792145557 @default.
- W2018715875 hasRelatedWork W2792187362 @default.
- W2018715875 hasRelatedWork W2946242728 @default.
- W2018715875 hasRelatedWork W4206749060 @default.
- W2018715875 hasRelatedWork W4214741764 @default.
- W2018715875 hasRelatedWork W4307701668 @default.
- W2018715875 hasVolume "8" @default.
- W2018715875 isParatext "false" @default.
- W2018715875 isRetracted "false" @default.
- W2018715875 magId "2018715875" @default.
- W2018715875 workType "article" @default.